Skip to content

Author

Günther U. Höglinger

We have 7 of 103 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Microglial dynamics associate with the spatial pattern of tau deposition in early Alzheimer’s disease

Neuroinflammation is implicated in Alzheimer’s disease (AD) pathogenesis, yet how changes in TSPO PET signal are associated with tau deposition, and how brain network architecture shapes this relationship remain poorly understood. We conducted a prospective, multimodal neuroimaging study in 56 participants: 35 amyloid-...

M. Öchsner, M. Brendel, N. Franzmeier et al. · 0 citations
Open access Oct 2026

Network‐dependent remote effects and local tau burden jointly shape neuronal dysfunction in Alzheimer's disease

Abstract BACKGROUND Tau pathology in Alzheimer's disease (AD) propagates along the brain's connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to tau‐harboring epicenters. METHODS One hundred thirty‐one amyloid‐posit...

Lukas Frontzkowski, Sebastian N. Roemer-Cassiano, Johannes S. Gnörich et al. · 0 citations
Review Open access Sep 2026

Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape

We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of dis...

A. Antonini, Robert E. Gross, María Lucia De León et al. · 0 citations
Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance, and NfL levels were elevated across diseases, and total α‐synuclein levels were associated with tau positivity.

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations
Open access Sep 2026

Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome

Background and Objectives Adults with Down syndrome (DS) have an increased risk of developing early Alzheimer disease. While our previous cross-sectional study investigated the blood proteome in the context of Alzheimer in DS, identifying CBLN4, CD14, C-X-C motif chemokine 17 (CXCL17), ectodysplasin A2 receptor (EDA2R)...

Olivia Wagemann, Georg S. Nuebling, K. Sandkühler et al. · 0 citations
Open access Sep 2026

Dynamic [18F]PI-2620 recording facilitates prediction of β-amyloid positivity and simultaneous staging of tau and neurodegeneration

Dynamic [18F]PI-2620 PET imaging facilitates assessment of the β-amyloid status and regional staging of tau and neurodegeneration during a single acquisition, and may reduce radiation exposure, streamline diagnostic workflows, and facilitate personalized disease profiling.

Johannes S. Gnörich, J. Kusche-Palenga, Agnes Kling et al. · 0 citations
Review Open access Aug 2026

Toward the prevention of clinically manifest Parkinson's disease.

The central purpose of this article is to define a desired destination around which the field can organize scientific innovation, including validated biological staging, risk stratification, longitudinal biomarker trajectories, trial enrichment, preventive endpoints, regulatory qualification, scalable implementation, a...

Günther U. Höglinger, Franziska Hopfner · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.